MAM
US ad revenues for Q1 seem flat
MUMBAI: Total advertising spending in the US in the first quarter fell 0.1 per cent from the year-ago period, at $30.1 billion, according to the latest figures from Kantar Media.
Cable expenditures were up by 5.2 per cent, thanks to an increase in the volume of ad time and stronger demand from restaurants and auto manufacturers. Spanish-language TV spending was up 13.5 per cent, marking its seventh consecutive quarter of double-digit growth. However, this is lower than the 15 per cent annual growth rate seen in 2012. The Spanish-language segment continues to be led by gains among national broadcast networks.
There was a 5.2 per cent decline in network TV spending, primarily due to weaker prime-time ratings. The Q1 comparisons were also hurt by the fact that ad money for NCAA Final Four Games has been shifted to April. Overall, sports programming did produce ad revenue gains for the broadcast networks though.
Spot TV spending was down, by 2.4 per cent. However, if you exclude cyclical political advertising, this area was essentially flat versus last year. Spending on syndication was down 1.1 per cent.
“It has been a lackluster start for 2013, with flat year-over-year results due in part to strong 2012 growth caused by political and Olympic ad spending,” said Kantar Media North America chief research officer Jon Swallen. “Data from the early second quarter are mixed, suggesting marketers are still being cautious and conservative with ad budgets. However, there are some bright spots, including healthy growth for Hispanic media and outdoor.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
